Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Mira-Bhayandar To Be Transformed Into 'Free WiFi' Zone In New Year, Says Transport Minister Pratap Sarnaik
Gold Falls ₹600 To ₹1,31,600/10g On Muted Global Trends, Rate-cut Jitters
Mumbai Tragedy: 47-Year-Old Labourer Falls To Death At Vikhroli Construction Site; Contractor Booked For Negligence
OSSI Survey Warns: Insurance Delays And High Costs Worsen India’s Growing Obesity Crisis
